GENERAL COMMENTS
Husain and colleagues report a study protocol for a systematic review and meta-analysis that compares pharmacological and psychological augmentation interventions for TRD.
The proposed study is important because it tackles a major public health problem and it seeks to addresses questions that have not yet been answered in the literature. Furthermore, given the multiple potential TRD interventions that are available, and the challenges of performing direct comparisons among them in prospective trials, the study described is a natural step forward.
The pre-registration plan, use of PRISMA guidelines, and approach to risk of bias are strengths.
I did not find the dates of the study reported here, or mention of whether the study is planned, in progress, or completed.
The choice to restrict the scope to "pharmacological and psychological augmentation" strategies has implications for how we interpret the findings. Patients who experience a partial response to an original treatment may be more likely to continue with augmentation, while patients who experience minimal response to an original treatment may be more likely to switch to a new treatment. The protocol as described may therefore lead to results that under-represent patients in the latter category. Similarly, since brain stimulation interventions are excluded from the protocol, the study may over-represent patients who are inappropriate for, or lack access to, brain stimulation treatments. What is the rationale for restricting the scope in these ways?
Because depression associated with neurologic disorders (e.g., Parkinson disease, epilepsy, dementia) likely differs in pathophysiology, I suggest excluding studies that exclusively enroll patients with comorbid neurologic disorders.
For the sensitivity analysis / meta-regression, in addition to the "potential explanatory factors" listed, I recommend examining (i) comorbid anxiety symptoms/diagnosis and (ii) level of social support and/or relationship status, if possible.
Finally, I would recommend that as the authors execute this study, they assess the feasibility of a individual-subject-level metaanalysis. Such an analysis would offer the opportunity to identify moderators of differential treatment response (e.g., level of treatment resistance or anxiety). These moderators are important because of the marked clinical heterogeneity encompassed by the "MDD" diagnosis, and because individualized treatment-matching is a critical part of clinical decision-making for TRD. Please leave your comments for the authors below This study protocol is ambitious, well designed and timely. Recommendations for minor revision are included below:
1. Unless missed by the reviewer, please include intended dates when the study will commence and end.
Response:
We would like to thank the Dr. Alpert for his time in reviewing our manuscript and his feedback. The study commencement date would be the date of the updated search (December 21 st , 2018). Our projected end date will be September 1 st , 2019. We have included this in the manuscript.
2. The term "licensed" treatment is unfamiliar to the reviewer, particularly when it comes to psychosocial treatments or to treatments that are still quasi-investigational such as minocycline. The reviewer suggests other terms such as evidenced based treatment
Thank you Dr. Alpert for raising this comment; we have updated the manuscript to include a change in wording to reflect a more commonly understood term.
3. The exclusion of studies on children and adolescents "due to differing treatment mechanisms in young people, particularly with regard to antidepressants" would seem to also apply to studies in geriatric populations where the etiology of depression may be more complicated by vascular or other factors. The reviewer would recommend excluding studies of individuals with explicitly late life depression (i.e., first onset of depression in older age).
Thank you very much for this comment; we would agree that studies that looked explicitly at late life depression should be excluded. Any studies that included an older population i.e. 18 years old to 65+ will be included, however, controlled for with sensitivity analysis to ensure that the older population is not a confounding factor. This has been updated in the manuscript.
4. Would suggest consistent use of term "augmenter" or "augmentation" treatment. The reviewer favours the latter.
Thank you for this comment; it has been adjusted to the latter term in the manuscript.
5. Would suggest either defining "continuation" treatments or using a different term. In much of the depression literature (e.g., Kupfer, Frank papers), the term "continuation" treatment referred to ongoing treatment beyond the point of depressive remission. In this manuscript, continuation treatment refers to the ongoing use of an initial treatment which has failed to establish remission and is now subject to augmentation with medication or psychotherapy. Terms such as initial or baseline treatment may help differentiate this from continuation treatment in the way this term has been used previously.
Thank you for this valid comment; we have adjusted the manuscript to describe continuation treatments as the 'initial treatment.'
Reviewer: 2
Reviewer Name: Brian J. Mickey Institution and Country: University of Utah and University of Michigan, USA Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below Husain and colleagues report a study protocol for a systematic review and meta-analysis that compares pharmacological and psychological augmentation interventions for TRD.
-I did not find the dates of the study reported here, or mention of whether the study is planned, in progress, or completed.
Response:
We would like to thank Dr. Mickey for their time in reviewing our manuscript and their feedback. The study commencement date would be the date of the updated search, December 21 st 2018. Our projected end date would be September 1 st , 2019. We have included these dates in the revised manuscript.
-The choice to restrict the scope to "pharmacological and psychological augmentation" strategies has implications for how we interpret the findings. Patients who experience a partial response to an original treatment may be more likely to continue with augmentation, while patients who experience minimal response to an original treatment may be more likely to switch to a new treatment. The protocol as described may therefore lead to results that under-represent patients in the latter category. Similarly, since brain stimulation interventions are excluded from the protocol, the study may over-represent patients who are inappropriate for, or lack access to, brain stimulation treatments. What is the rationale for restricting the scope in these ways?
We thank the review for this observation. By using a stricter definition of treatment resistant depression i.e. patients that have failed at least 2 antidepressant treatment trials, we have mitigated the bias of under representing patients that switch after a minimal response to the initial treatment. As we know from large naturalistic studies in depression such as the STAR-D, the remission rates decrease after each failed treatment trial; the overall remission rates reported in STAR-D for the medication options were 28%, 25%, 18%, and 10% at steps 1, 2, 3, and 4 respectively.
We accept the reviewer's feedback about the exclusion of brain stimulation studies and the inclusion of these studies is currently beyond the current scope of this review. However we have added this as a limitation of our study in the revised manuscript. .
-Because depression associated with neurologic disorders (e.g., Parkinson disease, epilepsy, dementia) likely differs in pathophysiology, I suggest excluding studies that exclusively enroll patients with comorbid neurologic disorders.
Thank you for this comment, we would agree with this and have made the adjustment in the protocol.
We thank you to the reviewer for this suggestion. Depending on data availability in included studies, comparisons of co-morbid anxiety symptoms and social support will be made quantitatively or qualitatively.
Finally, I would recommend that as the authors execute this study, they assess the feasibility of a individual-subject-level meta-analysis. Such an analysis would offer the opportunity to identify moderators of differential treatment response (e.g., level of treatment resistance or anxiety). These moderators are important because of the marked clinical heterogeneity encompassed by the "MDD" diagnosis, and because individualized treatment-matching is a critical part of clinical decision-making for TRD.
